IBB vs. GNOM
Compare and contrast key facts about iShares Nasdaq Biotechnology ETF (IBB) and Global X Genomics & Biotechnology ETF (GNOM).
IBB and GNOM are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019. Both IBB and GNOM are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
IBB vs. GNOM - Performance Comparison
Loading graphics...
IBB vs. GNOM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.88% | 27.98% | -2.41% | 3.76% | -13.69% | 0.95% | 26.01% | 6.12% |
GNOM Global X Genomics & Biotechnology ETF | -2.79% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 1.56% |
Returns By Period
In the year-to-date period, IBB achieves a 0.88% return, which is significantly higher than GNOM's -2.79% return.
IBB
- 1D
- 0.76%
- 1M
- -2.11%
- YTD
- 0.88%
- 6M
- 14.77%
- 1Y
- 37.04%
- 3Y*
- 9.92%
- 5Y*
- 2.62%
- 10Y*
- 6.92%
GNOM
- 1D
- 1.02%
- 1M
- -6.22%
- YTD
- -2.79%
- 6M
- 12.23%
- 1Y
- 44.15%
- 3Y*
- -3.13%
- 5Y*
- -13.13%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IBB vs. GNOM - Expense Ratio Comparison
IBB has a 0.47% expense ratio, which is lower than GNOM's 0.50% expense ratio.
Return for Risk
IBB vs. GNOM — Risk / Return Rank
IBB
GNOM
IBB vs. GNOM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IBB | GNOM | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.56 | 1.43 | +0.14 |
Sortino ratioReturn per unit of downside risk | 2.16 | 2.04 | +0.12 |
Omega ratioGain probability vs. loss probability | 1.28 | 1.26 | +0.02 |
Calmar ratioReturn relative to maximum drawdown | 2.86 | 2.25 | +0.61 |
Martin ratioReturn relative to average drawdown | 10.20 | 7.43 | +2.77 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| IBB | GNOM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.56 | 1.43 | +0.14 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.12 | -0.39 | +0.51 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.30 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.26 | -0.13 | +0.39 |
Correlation
The correlation between IBB and GNOM is 0.86, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
IBB vs. GNOM - Dividend Comparison
IBB's dividend yield for the trailing twelve months is around 0.23%, less than GNOM's 1.41% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.23% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
GNOM Global X Genomics & Biotechnology ETF | 1.41% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
IBB vs. GNOM - Drawdown Comparison
The maximum IBB drawdown since its inception was -62.85%, smaller than the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for IBB and GNOM.
Loading graphics...
Drawdown Indicators
| IBB | GNOM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.85% | -75.00% | +12.15% |
Max Drawdown (1Y)Largest decline over 1 year | -11.65% | -18.17% | +6.52% |
Max Drawdown (5Y)Largest decline over 5 years | -39.82% | -72.29% | +32.47% |
Max Drawdown (10Y)Largest decline over 10 years | -39.82% | — | — |
Current DrawdownCurrent decline from peak | -4.16% | -59.83% | +55.67% |
Average DrawdownAverage peak-to-trough decline | -21.30% | -40.12% | +18.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.27% | 5.51% | -2.24% |
Volatility
IBB vs. GNOM - Volatility Comparison
The current volatility for iShares Nasdaq Biotechnology ETF (IBB) is 8.38%, while Global X Genomics & Biotechnology ETF (GNOM) has a volatility of 10.76%. This indicates that IBB experiences smaller price fluctuations and is considered to be less risky than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| IBB | GNOM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.38% | 10.76% | -2.38% |
Volatility (6M)Calculated over the trailing 6-month period | 14.50% | 19.71% | -5.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.01% | 31.21% | -7.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.87% | 33.65% | -11.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.37% | 34.30% | -10.93% |